Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Inflammatory Bowel Disease Drugs Market – reveals latest opportunities, trends, projected revenues, and competitive landscape. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global inflammatory bowel disease drugs market is projected to reach a market value of US$xxbillion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis and growing investment in R&D by pharmaceutical companies are major factor that drives the demand for IBD drugs. Some other key factors that propel the market growth are the growing adoption of drugs for inflammatory bowel disease treatment and maintenance therapy; rising awareness for Crohn’s disease and ulcerative colitis in developing countries; and technological advancements. In addition, the COVID-19 pandemic has a significant impact on the IBD drugs market.
Visiongain’s report shows you the potential revenue streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the inflammatory bowel disease drugs industry.
How this report will benefit you
Visiongain’s 330+ page report provides 199 tables and 147 charts/graphs. Our new study is envisioned for anyone requiring commercial in-depth analyses for the global IBD drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for IBD drugs. Get the financial analysis of the overall market and different segments including drug class, indication, patient demographics, end-user, and distribution channel and capture higher market share. High opportunity remains in this fast-growing inflammatory bowel disease drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects
- Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
- It also includes growth rates for different 4 regional markets along with 11 countries and COVID-19 impact analysis on each market
- The profiles of the top 13 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
- The COVID-19 has a positive impact on the IBD drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Along with revenue prediction for the overall global inflammatory bowel disease market, there is segmentation by region for 4 regional markets including the U.S., Japan, Europe5, BRIC, and RoW and 11 major countries.
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
- Biologics
- Aminosalicylates
- Corticosteroids
- Antibiotics
- Immunomodulators
- Others
- Crohn’s Disease
- Ulcerative Colitis
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S.
- Japan
- Europe5
- Germany
- UK
- France
- Italy
- Spain
- BRIC
- Brazil
- Russia
- India
- China
- RoW
Detailed profiles of 13 leading companies that are operating in the market
The report includes profiles of 13 major companies involved in the IBD drugs market. The companies profiled in this report include: AbbVie, Janssen Biotech, Allergan plc., Takeda Pharmaceuticals, Pfizer Inc., Novartis AG, UCB Pharma S.A., Biogen Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Celgene Corporation, Celltrion Corporation, and Ferring B.V.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
In summary, our 330+ page report delivers you with the following knowledge:
- Revenue forecasts from 2021 to 2031 for the global IBD drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
- Detailed profiles of top 13 IBD drugs manufacturers, with financial overviews
- Revenue forecasts from 2021 to 2031 for 4 regional markets – See forecasts for the IBD drugs market in the U.S., Japan, Europe5, BRIC, and RoW.
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the IBD drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.
The Inflammatory Bowel Disease Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the IBD drugs industry.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1. World Inflammatory Bowel Disease Drugs (IBD) Market: Overview of Findings
- 1.2. Global Inflammatory Bowel Disease Drugs Market Segmentation
- 1.3. Why You Should Read This Report
- 1.1 Main Questions Covered in the Analysis
- 1.4. What This Report Delivers
- 1.5. Key Questions Answered By This Analytical Report Include:
- 1.6. Who is This Report For?
- 1.7. Methodology
- 1.1.1 Primary Research
- 1.1.2 Secondary Research
- 1.1.3 Market Evaluation and Forecasting Methods
- 1.8. COVID-19 Impact: Recovery Scenarios
- 1.9. Frequently Asked Questions (FAQs)
- 1.10. Associated Visiongain Reports
- 1.11. About Visiongain
- 2 Executive Summary
- 3 Introduction to the Inflammatory Bowel Disease Drug Market
- 3.1 What is Inflammatory Bowel Disease (IBD)?
- 3.2 Classification of IBD
- 3.3 Symptoms and Diagnosis of IBD
- 3.4 Multifactorial Causes of IBD
- 3.5 How common is IBD?
- 3.6 What Are the Treatment Options for IBD?
- 3.6.1 Aminosalicylates – The Most Common Therapy
- 3.6.2 Antibiotics – Supporting Evidences
- 3.6.3 Corticosteroids – growth is majorly driven by Uceris
- 3.6.4 Immunomodulators – Slow to Act?
- 3.6.5 Biologics – Not Cost-effective?
- 3.7 Treatment Goals for IBD – Treat-to-Target Approach?
- 3.8 Treatment Algorithm
- 3.9 Management of Inflammatory Bowel Disease – 2020
- 4 Market Dynamics
- 4.1 Drivers Analysis – Inflammatory Bowel Disease Drugs Market
- 4.1.1 Increasing Disease Incidence in Most National Markets
- 4.1.2 Better Diagnosis of IBD
- 4.1.3 Delivery Systems Improve Existing Drugs of IBD
- 4.2 Opportunity Analysis – Inflammatory Bowel Disease Drugs Market
- 4.2.1 Biological Drugs – Driving the Market Significantly
- 4.2.2 Socioeconomic Costs of IBD
- 4.3 Restrains Analysis – Inflammatory Bowel Disease Drugs Market
- 4.3.1 Lack of Understanding of Disease Aetiology
- 4.3.2 Compliance – Frequent Dosing is Inconvenient
- 4.3.3 Limitations of Biologics – Side Effect Profiles
- 4.4 Challenges Analysis – Inflammatory Bowel Disease Drugs Market
- 4.4.1 The Possible Development of Alternative Treatments
- 4.4.2 Surgery – Treatment for Recalcitrant IBD
- 4.4.3 Health Care Cost Containment
- 4.5 Porter’s Five Forces Analysis – Inflammatory Bowel Disease Drugs Market
- 4.5.1 Bargaining Power of Supplier: Low
- 4.5.2 Bargaining Power of Buyer: Moderate
- 4.5.3 Competitive Rivalry: High
- 4.5.4 Threat of New Entrants: High
- 4.5.5 Threat of Substitutes: High
- 4.6 SWOT Analysis – Inflammatory Bowel Disease Drugs Market
- 4.6.1 Strengths
- 4.6.2 Weaknesses
- 4.6.3 Opportunities
- 4.6.4 Threats
- 4.7 PEST Analysis – Inflammatory Bowel Disease Drugs Market
- 4.7.1 Political
- 4.7.2 Economical
- 4.7.3 Social
- 4.7.4 Technological
- 5 Global Inflammatory Bowel Diseases Drug Market, 2021-2031
- 5.1 Global Inflammatory Bowel Disease Drugs Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2031
- 5.1.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
- 5.1.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
- 5.1.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
- 5.1.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
- 6 Global Inflammatory Bowel Diseases Drug Market by Indication, 2021-2031
- 6.1 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031
- 6.1.1 Recovery Forecasts (V, U, W, L)
- 6.2 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031
- 6.2.1 Recovery Forecasts (V, U, W, L)
- 7 Global Inflammatory Bowel Disease Drugs Market Size Forecast 2021-2031 by Drug Class
- 7.1 Global Inflammatory Bowel Disease Drugs Market for Biologics Segment: Revenue Forecast 2021-2031
- 7.2 Biologic Therapies Forecast 2021-2031 – Largest Revenue Grossing Segment
- 7.2.1 Recovery Forecasts (V,U, W, L)
- 7.3 Aminosalicylates Forecast 2021-2031: The Steady Growth
- 7.3.1 Recovery Forecasts (V,U, W, L)
- 7.4 Corticosteroids Forecast 2021-2031: Rescue therapies
- 7.4.1 Recovery Forecasts (V,U, W, L)
- 7.5 Antibiotics Forecast 2021-2031: Growing Despite Challenges
- 7.5.1 Recovery Forecasts (V,U, W, L)
- 7.6 Immunomodulators Forecast 2021-2031 – Will Grow at Moderate Pace
- 7.6.1 Recovery Forecasts (V,U, W, L)
- 7.7 Other Drug Classes Segment Forecast 2021-2031 – Will Grow at a Significant Rate
- 7.7.1 Recovery Forecasts (V,U, W, L)
- 8 Global Inflammatory Bowel Disease by Distribution Channel, 2021-2031
- 8.1 Hospital Pharmacies Forecast 2021-2031
- 8.1.1 Recovery Forecasts (V,U, W, L)
- 8.2 Retail Pharmacies Forecast 2021-2031
- 8.2.1 Recovery Forecasts (V,U, W, L)
- 8.3 Online Pharmacies Forecast 2021-2031
- 8.3.1 Recovery Forecasts (V,U, W, L)
- 9 Leading National Markets: Sales Outlooks, 2021- 2031
- 9.1 Global Inflammatory Bowel Disease Drugs Market Overview: Regional Distribution, 2021- 2031
- 9.2 Inflammatory Bowel Disease Drugs - Leading National Markets 2020
- 9.3 The US IBD Drugs Market, 2021-2031 – The World Leader in the Inflammatory Bowel Disease Drugs Market
- 9.3.1 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
- 9.3.2 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
- 9.3.3 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
- 9.3.4 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
- 9.3.5 U.S. IBD Drugs Market By Drug Class, 2021-2031
- 9.3.6 U.S. IBD Drugs Market By Indication, 2021-2031
- 9.3.7 U.S. IBD Drugs Market By Distribution Channel, 2021-2031
- 9.4 The Japanese IBD Drugs Market, 2021-2031- Developed Healthcare Infrastructure is Expected to Boost the Market Growth
- 9.4.1 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
- 9.4.2 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
- 9.4.3 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
- 9.4.4 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
- 9.4.5 Japan IBD Drugs Market By Drug Class, 2021-2031
- 9.4.6 Japan IBD Drugs Market By Indication, 2021-2031
- 9.4.7 Japan IBD Drugs Market By Distribution Channel, 2021-2031
- 9.5 The EU5 IBD Drugs Market, 2021-2031
- 9.5.1 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
- 9.5.2 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
- 9.5.3 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
- 9.5.4 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
- 9.5.5 EU5 IBD Drugs Market By Drug Class, 2021-2031
- 9.5.6 EU5 IBD Drugs Market By Indication, 2021-2031
- 9.5.7 EU5 IBD Drugs Market By Distribution Channel, 2021-2031
- 9.5.8 Germany Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.5.8.1 Germany Accounted For The Largest Revenue Share In The EU5 Inflammatory Bowel Disease Drugs Market
- 9.5.8.2 Presence of Well-Established Healthcare Infrastructure
- 9.5.9 UK Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.5.9.1 Increasing Prevalence Of IBD In The UK Is Driving The Demand Of Advanced Drugs
- 9.5.9.2 Growing Awareness For The IBD Among People
- 9.5.10 France Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.5.10.1 Availability Of Advanced Healthcare In This Region Will Propel The Demand For Inflammatory Bowel Disease Drugs
- 9.5.10.2 Growing Research Funding Is Boosting The French Market
- 9.5.11 Italy Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.5.11.1 One Of The Fastest Growing Market In EU5 Region
- 9.5.11.2 Growing Number Of Product Launches Will Boost The Regional Market Growth
- 9.5.12 Spain Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.5.12.1 Rising Prevalence Of IBD In This Region Will Drive The Spain Market Growth
- 9.5.12.2 Rising Number Healthcare Awareness Programs By The Government
- 9.6 The BRIC IBD Drugs Market, 2021-2031 – Fastest Growing Region in the Global IBD Market
- 9.6.1 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
- 9.6.2 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
- 9.6.3 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
- 9.6.4 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
- 9.6.5 BRIC IBD Drugs Market By Drug Class, 2021-2031
- 9.6.6 BRIC IBD Drugs Market By Indication, 2021-2031
- 9.6.7 BRIC IBD Drugs Market By Distribution Channel, 2021-2031
- 9.6.8 Brazil Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.6.8.1 Developing Healthcare Infrastructure Is Expected To Have Positive Impact On The Regional Market Growth
- 9.6.8.2 Medical Tourism In Brazil Will Have Positive Impact On The Regional Market Growth
- 9.6.9 Russia Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.6.9.1 Increasing investment by the government on healthcare infrastructure is a major factor that will boost the market growth
- 9.6.9.2 Rising Awareness For IBD Among Healthcare Professionals And People
- 9.6.10 India Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.6.10.1 One of the fastest growing market in BRIC region
- 9.6.10.2 Developing Infrastructure In India
- 9.6.11 China Inflammatory Bowel Disease Drugs Market, 2021- 2031
- 9.6.11.1 Fastest Growing Region In The Global IBD Market
- 9.6.11.2 Presence Of Leading Manufacturers In This Region
- 10 The R&D Pipeline for Inflammatory Bowel Diseases
- 10.1 Top Marketed and pipeline products – Launch dates and Patent expiry
- 10.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
- 10.2.1 STI-0529, Sublimity Therapeutics (formerly CyCol, Sigmoid Pharma)
- 10.2.2 PF-04236921 (Pfizer)
- 10.2.3 QAX 576 (Novartis)
- 10.2.4 TNF Kinoid (Neovacs)
- 10.2.5 Vidofludimus (4SC) – Suspended
- 10.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
- 10.2.7 Entyvio (Vedolizumab, Takeda)
- 10.2.8 Risankizumab, Abbvie and Boehringer Ingelheim
- 10.2.9 Brazikumab, Allergan (Under collaboration agreement with AstraZeneca & Amgen)
- 10.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
- 10.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
- 10.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
- 10.3.3 MEDI 7183/AMG 181 (AstraZeneca)
- 10.3.4 Etrolizumab (Roche)
- 10.3.5 PF-00547659 (Pfizer)
- 10.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
- 10.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
- 10.4 TNF-α Inhibitors – a Specific Target
- 10.4.1 AVX-470 (Avaxia Biologics)
- 10.4.2 Ozoralizumab (ALX-0061, Ablynx)
- 10.5 Stem Cell Therapies – Basis for a Cure?
- 10.5.1 Ovasave (TxCell)
- 10.5.2 MultiStem (Athersys and Pfizer)
- 10.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
- 10.5.4 Cx601 (TiGenix)
- 10.6 JAK Inhibitors – New Target Pathway
- 10.6.1 JNJ-54781532 (Janssen)
- 10.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
- 10.7 Toll-like Receptor Agonists
- 10.7.1 BL-7040 (BioLineRX)
- 10.7.2 Kappaproct (InDex Pharmaceuticals)
- 10.8 Other Classes of Agent
- 10.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
- 10.8.2 GLPG0974 (Galapagos)
- 10.8.3 RPC1063 (Receptos/now Celgene)
- 10.8.4 SGX203 (Soligenix)
- 10.8.5 Mongersen (GED-0301, Celgene)
- 10.8.6 Tetomilast (OPC-6535, Otsuka)
- 10.8.7 Laquinimod (Active Biotech)
- 10.8.8 RHB-104 (RedHill Biopharma)
- 10.8.9 Ozanimod (Celgene)
- 10.8.10 GED-0301 (Celgene)
- 10.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
- 10.9.1 Adalimumab Biosimilars
- 10.9.2 Infliximab Biosimilars
- 11 Leading Companies in the IBD Pharmaceuticals Market
- 11.1 Company Share Analysis
- 11.2 Strategic Developments, 2017-2020
- 11.3 Abbvie
- 11.3.1 Company Information
- 11.3.2 Business Overview
- 11.3.3 Pipeline Overview
- 11.3.4 Product Portfolio
- 11.3.5 Recent Developments, 2017-2020
- 11.4 Janssen Biotech
- 11.4.1 Company Information, 2020
- 11.4.2 Business Overview
- 11.4.3 Pipeline Overview
- 11.4.4 Product Portfolio
- 11.4.5 Recent Developments, 2017-2020
- 11.5 Allergan plc
- 11.5.1 Company Information, 2020
- 11.5.2 Business Overview
- 11.5.3 Pipeline Overview:
- 11.5.4 Product Portfolio
- 11.5.5 Recent Developments, 2017-2020
- 11.6 Takeda Pharmaceuticals
- 11.6.1 Company Information, 2020
- 11.6.2 Business Overview
- 11.6.3 Pipeline Overview
- 11.6.4 Product Portfolio
- 11.6.5 Recent Developments, 2017-2020
- 11.7 Pfizer
- 11.7.1 Company Information, 2020
- 11.7.2 Business Overview
- 11.7.3 Pipeline Overview
- 11.7.4 Product Portfolio
- 11.7.5 Recent Developments, 2017-2020
- 11.8 Novartis AG
- 11.8.1 Company Information, 2020
- 11.8.2 Business Overview
- 11.8.3 Pipeline Overview
- 11.8.4 Product Portfolio
- 11.8.5 Recent Developments, 2017-2020
- 11.9 UCB Pharma S.A.
- 11.9.1 Company Information, 2020
- 11.9.2 Business Overview
- 11.9.3 Pipeline Overview
- 11.9.4 Product Portfolio
- 11.10 Biogen Inc.
- 11.10.1 Company Information, 2020
- 11.10.2 Business Overview
- 11.10.3 Product Portfolio
- 11.11 Gilead Sciences, Inc.
- 11.11.1 Company Information, 2020
- 11.11.2 Business Overview
- 11.11.3 Pipeline Overview
- 11.11.4 Product Portfolio
- 11.12 Roche
- 11.12.1 Company Information, 2020
- 11.12.2 Business Overview
- 11.12.3 Pipeline Overview
- 11.12.4 Recent Developments, 2017-2020
- 11.13 Celgene Corporation
- 11.13.1 Company Information, 2020
- 11.13.2 Business Overview
- 11.13.3 Pipeline Overview
- 11.13.4 Product Portfolio
- 11.13.5 Recent Developments, 2017-2020
- 11.14 Celltrion Corporation
- 11.14.1 Company Information, 2020
- 11.14.2 Pipeline Overview
- 11.14.3 Product Portfolio
- 11.15 Ferring B.V.
- 11.15.1 Company Information, 2020
- 11.15.2 Business Overview
- 11.15.3 Product Portfolio
- 12 Conclusions & Recommendations
- 12.1 Conclusion
- 12.2 Recommendations
- List of Tables
- Table 1 Global Inflammatory Bowel Disease Drugs Market, 2020 & 2031 (US$billion, CAGR%)
- Table 2 Differentiating Crohn’s Disease and Ulcerative Colitis
- Table 3 Clinical Presentation Crohn’s Disease and Ulcerative Colitis
- Table 4 Worldwide Prevalence Rates for IBD, 2020-2020
- Table 5 Worldwide Incidence Rates for IBD, 2020-2020 (Newly diagnosed cases per 100,000 person-years)
- Table 6 Geographical Variations in the Incidence of IBD, 2020
- Table 7 Treatment Recommendations for IBD
- Table 8 Medical Approach for IBD Management, 2020
- Table 9 Indications
- Table 10 Other Drug Types Used to Treat IBD, 2020
- Table 11 Aminoacylates for IBD Management, 2020
- Table 12 Antibiotics for IBD Management, 2020
- Table 13 Immunomodulators for IBD Management, 2020
- Table 14 Biologics for IBD Management, 2020
- Table 15 Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 16 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 17 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 18 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 19 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 20 Global Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
- Table 21 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 22 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 23 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 24 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 25 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 26 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 27 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
- Table 28 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion,
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook